Lilly's tirzepatide drives deep drops in blood sugar and body weight in diabetes phase 3

Eli Lilly’s tirzepatide has significantly reduced blood sugar and body weight in Type 2 diabetics in a late-phase clinical trial. The release of the top-line data provides early validation of Lilly’s decision to place a big bet on the dual GIP/GLP-1 agonist.